GlassScriptPhysician profile
Mahmoud Sheikh-Khalil
NPI 1801835897
$2,683.36
in general payments reported to CMS, 2019-2025
17 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $129 · 2021: $111 · 2022: $104 · 2023: $583 · 2024: $237 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353 · Travel and Lodging: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.76 |
| Travel and Lodging | $842.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,238.19 | 2019-2025 | Aveir, Jot Dx |
| Medtronic, INC. | $485.23 | 2021-2025 | Turbohawk, Concertotm, Enteer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $290.74 | 2021-2025 | Lifevest |
| Cardiovascular Systems INC. | $148.28 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $105.61 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $92.84 | 2019-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $68.27 | 2023-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $45.49 | 2023 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $43.33 | 2019-2023 | Camzyos, Eliquis |
| Irhythm Technologies, INC. | $33.15 | 2022-2023 | Zio Xt Patch |
| Boston Scientific Corporation | $26.05 | 2020 | |
| Kestra Medical Technology Services, INC. | $25.10 | 2025 | Assure Wcd |
| Pfizer INC. | $19.51 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.16 | 2024 | |
| Terumo Medical Corporation | $16.21 | 2025 | Angio-Seal |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $14.47 | 2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $13.73 | 2025 | Lokelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmoud Sheikh-Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.